Ozempic vs Mounjaro: Which GLP-1 Produces More Weight Loss?
Medically reviewed by Medical Advisory Board Last reviewed 2026-06-15
Semaglutide vs tirzepatide — different mechanisms, different results
Ozempic (semaglutide) and Mounjaro (tirzepatide) are both weekly GLP-1 injections, but Mounjaro also targets the GIP receptor — and that second mechanism produces meaningfully more weight loss in head-to-head trials. This guide compares mechanism, weight-loss results, side effects, cost, and who each drug suits.
Ozempic vs. Mounjaro is the most-asked GLP-1 question right now, and for good reason. On the surface, they look similar: both are weekly injections for Type 2 diabetes. But they are not the same drug, and they do not produce the same results. Ozempic is semaglutide, a pure GLP-1 receptor agonist. Mounjaro is tirzepatide, a dual GIP/GLP-1 receptor agonist that works through two pathways simultaneously.
For a broader look at the GLP-1 drug class, start with our GLP-1 peptides guide. If weight loss stalls on either drug, see our GLP-1 plateau guide. And if weight loss, not diabetes, is your primary goal, see how each drug compares with the other's weight-loss-approved sibling brand: Wegovy vs Mounjaro and Zepbound vs Ozempic.
Partner · Opt Health
Want medical weight loss instead of another diet?
Opt Health prescribes and monitors GLP-1 therapy against real labs — insulin, A1C, lipids, thyroid, hormones — so the plan fits your physiology rather than a generic protocol. Medication ships to your door.
See Opt Health's weight-loss program →Ozempic vs Mounjaro: Head-to-Head
| Factor | Ozempic (semaglutide) | Mounjaro (tirzepatide) |
|---|---|---|
| Drug class | GLP-1 receptor agonist | GIP + GLP-1 dual receptor agonist |
| FDA approval | Type 2 diabetes (Ozempic); obesity (Wegovy) | Type 2 diabetes (Mounjaro); obesity (Zepbound) |
| Dosing | 0.5–2 mg weekly injection | 2.5–15 mg weekly injection |
| Average weight loss (trials) | ~12–15% body weight (SUSTAIN/STEP trials) | ~15–22% body weight (SURPASS/SURMOUNT trials) |
| A1C reduction | Strong (SUSTAIN series) | Stronger at higher doses (SURPASS series) |
| GI side effects | Nausea, vomiting, diarrhea during titration | Similar; possibly higher nausea rates at initiation |
| CV outcomes data | Yes (SUSTAIN-6, SELECT trial) | Emerging (SURPASS-CVOT pending full publication) |
| Cost (without coverage) | ~$900–$1,000/month | ~$1,000–$1,100/month |
Why Mounjaro Produces More Weight Loss
Semaglutide acts on GLP-1 receptors, slowing gastric emptying and reducing appetite through brain signaling. Tirzepatide does all of that but also activates GIP receptors — and GIP appears to amplify GLP-1's appetite-suppressing effect and improve the metabolic handling of fat. The result in the SURMOUNT-1 trial was average weight loss of 20.9% at 72 weeks on 15 mg tirzepatide versus 14.9% for semaglutide 2.4 mg (Wegovy) in the STEP-1 trial, though the trials weren't directly head-to-head.
A 2024 real-world study (JAMA) comparing the two drugs directly did show statistically significant greater weight loss with tirzepatide at one year.
When Ozempic Is the Better Choice
Ozempic may suit you better if:
- You or your insurer are more comfortable with its longer safety and outcomes track record (it has been available since 2017).
- You have established cardiovascular disease — SELECT trial data directly supports semaglutide for CV risk reduction.
- Supply or access favors semaglutide in your area.
- You have previously tolerated semaglutide and are dose-stable.
When Mounjaro Is the Better Choice
Mounjaro may suit you better if:
- Maximizing weight loss is the primary goal and you are willing to titrate to 10–15 mg.
- Blood sugar control at high A1C needs stronger pharmacological support.
- You have not responded well enough to semaglutide.
If you are choosing between the weight-loss-approved brands, see our Wegovy vs Zepbound guide for the obesity-indication framing.
The Verdict
For weight loss, tirzepatide (Mounjaro/Zepbound) has better trial numbers. For CV outcomes evidence and longer-term safety data, semaglutide (Ozempic/Wegovy) has the edge. Both are excellent drugs. If weight loss is your primary goal and you have no contraindications, the evidence currently favors tirzepatide. If cardiovascular protection matters most, semaglutide has the stronger outcomes data. A clinician who knows your full history is the right person to make the call — start with our free metabolic assessment or book a consultation.
What to Look For in a Body-Composition Scale
A bioimpedance scale trends body fat and muscle rather than just weight — useful when the number stalls but your composition is improving. The absolute body-fat % isn't lab-accurate, so use it for TRENDS at a consistent time of day. Choose one that syncs to an app so you can watch the trend line.
Frequently Asked Questions
Is Mounjaro stronger than Ozempic?
In terms of average weight loss in clinical trials, yes — tirzepatide (Mounjaro/Zepbound) produces more weight loss on average than semaglutide (Ozempic/Wegovy). The SURMOUNT-1 trial showed ~20.9% body weight loss at the highest tirzepatide dose versus ~14.9% in the semaglutide STEP-1 trial, though these were separate studies. A 2024 real-world head-to-head study confirmed meaningfully greater weight loss with tirzepatide at one year.
Can you switch from Ozempic to Mounjaro?
Yes, switching is done under medical supervision. Because both drugs affect GLP-1 receptors, the transition typically involves stopping semaglutide and starting tirzepatide at a low dose with titration. Some people switch when Ozempic stops producing results; others switch for insurance or supply reasons. Your clinician will guide the timing and starting dose.
Are Ozempic and Mounjaro covered by insurance?
Coverage varies significantly by insurer and indication. Both are FDA-approved for Type 2 diabetes, which has broader coverage. The obesity-branded versions (Wegovy and Zepbound) face more variable insurance hurdles. Many commercial plans have added GLP-1 coverage in 2024–2025, but Medicare Part D coverage for weight loss specifically was limited until the Treat and Reduce Obesity Act provisions. Always verify your plan's prior authorization requirements before starting.
What are the side effects of Ozempic vs Mounjaro?
Both cause similar GI side effects — nausea, vomiting, diarrhea, and constipation — most prominently during dose escalation. These typically improve over the first 4–8 weeks. Both carry a black-box warning about thyroid C-cell tumors based on rodent data (clinical significance unclear). Pancreatitis is a rare risk with both. Mounjaro may have slightly higher early nausea rates due to the GIP component. Neither should be used in pregnancy.
Topic updates
Get the weekly metabolic health roundup
Insulin resistance, blood sugar, visceral fat, GLP-1 plateaus, metabolic syndrome, and weight-loss physiology.
Want weight loss handled by a physician who works from your labs? See how Opt Health does it →
Check Where You Stand
Take our free health assessment to understand your metabolic, hormonal, and recovery risk factors — and get personalized recommendations.
Take the Free Assessment →Free · Takes 5 minutes · Instant results
Related Comparisons
-
Ozempic vs Wegovy: Same Drug (Semaglutide), Different Use and Dose
Ozempic vs Wegovy: both are semaglutide — the real differences in approval, dose, and coverage.
-
Saxenda vs Mounjaro: Obesity-approved Daily Shot vs Diabetes-branded Dual-action Drug Compared
Saxenda vs Mounjaro: obesity-approved daily shot vs diabetes-branded dual-action drug — approval pathway explained.
-
Foundayo vs Ozempic: Obesity-approved Pill vs Diabetes-branded Weekly Shot Compared
Foundayo vs Ozempic: obesity-approved daily pill vs diabetes-branded weekly shot — approval pathway explained.
See more related comparisons
-
Foundayo vs Mounjaro: Obesity-approved Pill vs Diabetes-branded Dual-action Drug Compared
Foundayo vs Mounjaro: obesity-approved daily pill vs diabetes-branded dual-action drug — approval pathway explained.
-
Berberine vs Ozempic: Is Berberine Really 'Nature's Ozempic'?
Berberine vs Ozempic: why 'nature's Ozempic' is a stretch, and what each actually does.
-
Ozempic vs Metformin: Weight Loss and Blood Sugar Compared
Ozempic vs metformin: weight loss, blood sugar, cost, and when to use each (or both).
-
Wegovy vs Mounjaro: On-label Weight-loss Approval vs Off-label Diabetes Drug Compared
Wegovy vs Mounjaro: on-label weight-loss approval vs off-label diabetes drug compared.
-
Zepbound vs Ozempic: On-label Weight-loss Approval vs Off-label Diabetes Drug Compared
Zepbound vs Ozempic: on-label weight-loss approval vs off-label diabetes drug compared.
Affiliate disclosure: The Metabolic Journal is reader-supported. Some links above are affiliate or referral links and we may earn a commission at no extra cost to you. As an Amazon Associate we earn from qualifying purchases. Products are chosen on the merits; commissions never influence what we recommend. This is general information, not medical advice — talk to your clinician before acting.